Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791407 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL20622101 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL19242291 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL26491308 | 0.98 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL26488994 | 0.95 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL24654963 | 0.95 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL20841352 | 0.94 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3PRCPDPP7 | |
| SCHEMBL21226033 | 0.93 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL24833572 | 0.93 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3PRCP | |
| SCHEMBL21846836 | 0.91 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3PRCPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299100-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | YAP1, TEAD3, TEAD2 | SLC6A2 3704/4885SLC6A4 4472/4885SLC6A3 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.